438492-33-2 Usage
General Description
Methyl 1-benzyl-4-phenylpyrrolidine-3-carboxylate is a chemical compound with a complex molecular structure and a variety of potential applications. Methyl 1-benzyl-4-phenylpyrrolidine-3-carboxylate is a derivative of pyrrolidine, a five-membered nitrogen-containing heterocycle, and it contains a carboxylate ester group and a phenyl and benzyl substituent. It is commonly used in the field of organic chemistry as a building block for the synthesis of other compounds, and it may also have potential pharmacological or biological activities. Additionally, its unique structure makes it of interest in the study of structure-activity relationships and the development of new chemical entities. Overall, Methyl 1-benzyl-4-phenylpyrrolidine-3-carboxylate is a versatile and potentially valuable compound with a wide range of potential applications in chemistry and related fields.
Check Digit Verification of cas no
The CAS Registry Mumber 438492-33-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,8,4,9 and 2 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 438492-33:
(8*4)+(7*3)+(6*8)+(5*4)+(4*9)+(3*2)+(2*3)+(1*3)=172
172 % 10 = 2
So 438492-33-2 is a valid CAS Registry Number.
438492-33-2Relevant articles and documents
The convenient synthesis of 3-alkyloxycarbonylpyrrolidine derivatives
Dong, Jingchao,Kou, Binbin,Li, Runtao,Cheng, Tieming
, p. 935 - 939 (2002)
A series of 3-alkyloxycarbonylpyrrolidine derivatives are readily achieved via 1,3-dipolar cycloaddition of α,β-unsaturated esters with nonstabilized azomethine ylides in the presence of samarium diiodide.
1,3-Dipolar cycloaddition of unstabilised azomethine ylides by Lewis base catalysis
Pandiancherri, Shveta,Ryan, Sarah J.,Lupton, David W.
, p. 7903 - 7911 (2013/07/05)
Lewis base catalysed 1,3-dipolar cycloaddition between α,β- unsaturated acyl fluorides and N-[(trimethylsilyl)methyl]amino ethers has been achieved using 1 mol% DMAP. Competition experiments and 19F-NMR studies indicate that the cycloaddition o
Tricyclic indanyls as integrin inhibitors
-
Page/Page column 19-20, (2010/02/10)
The present invention is directed to substituted indanyl compounds of Formula (I): Useful for treating integrin-mediated disorders such as, but not limited to unstable angina, thromboemboic disorders, osteoporosis, growth and metastasis of malignant tumors, diabetic retinopathy, arthritis, viral disease and surgical adhesions.
